Published in Am J Hum Genet on June 01, 1998
Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet (2005) 3.03
Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection. Am J Hum Genet (2003) 1.66
Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc Natl Acad Sci U S A (1999) 1.54
Genomewide linkage scan for bipolar-disorder susceptibility loci among Ashkenazi Jewish families. Am J Hum Genet (2004) 1.29
Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol (2012) 1.28
Fine mapping on chromosome 10q22-q23 implicates Neuregulin 3 in schizophrenia. Am J Hum Genet (2009) 1.27
On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet (2010) 1.17
The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol Biomarkers Prev (2008) 1.03
Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet (1999) 1.03
A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int (2013) 1.02
Common deletion of SMAD4 in juvenile polyposis is a mutational hotspot. Am J Hum Genet (2002) 1.00
Founder populations and their uses for breast cancer genetics. Breast Cancer Res (2000) 0.99
Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer (2000) 0.98
De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer. J Med Genet (2001) 0.97
Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet (2005) 0.94
How old is this mutation? - a study of three Ashkenazi Jewish founder mutations. BMC Genet (2010) 0.93
Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families. Br J Cancer (2000) 0.92
Age-dependent penetrance of different germline mutations in the BRCA1 gene. J Clin Pathol (2009) 0.91
Offspring gender ratio and the rate of recurrent spontaneous miscarriages in jewish women at high risk for breast/ovarian cancer. Am J Hum Genet (2004) 0.90
Identification of a founder BRCA2 mutation in Sardinia. Br J Cancer (2000) 0.89
Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. Proc Natl Acad Sci U S A (2004) 0.89
BRCA1 and BRCA2 mutations in Scotland and Northern Ireland. Br J Cancer (2003) 0.88
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet (2011) 0.87
A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet (2000) 0.86
Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet (2012) 0.84
The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. Breast Cancer Res Treat (2015) 0.83
Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer. Gut (2002) 0.83
Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. BMC Med Genet (2006) 0.82
A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families. Br J Cancer (2001) 0.80
Identification of a founder BRCA2 mutation in Sardinian breast cancer families. Fam Cancer (2007) 0.80
Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999. Eur J Med Genet (2007) 0.79
The Tyr978X BRCA1 mutation: occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-Ashkenazi Jews. Fam Cancer (2005) 0.78
The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers. Fam Cancer (2004) 0.78
Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2. J Community Genet (2010) 0.77
Novel BRCA1 deleterious mutation (c.1949_1950delTA) in a woman of Senegalese descent with triple-negative early-onset breast cancer. Oncol Lett (2011) 0.76
Estimation of the RNU2 macrosatellite mutation rate by BRCA1 mutation tracing. Nucleic Acids Res (2014) 0.75
BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study. Fam Cancer (2015) 0.75
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53
A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature (1996) 27.61
Identification of the breast cancer susceptibility gene BRCA2. Nature (1996) 17.14
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet (1995) 5.83
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet (1996) 4.36
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet (1997) 4.16
Population genetics of BRCA1 and BRCA2. Am J Hum Genet (1997) 3.28
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet (1996) 2.97
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82
Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet (1996) 2.40
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet (1997) 2.33
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet (1997) 2.28
Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13. Genomics (1996) 1.41
Breast cancer and BRCA1 mutations. N Engl J Med (1996) 0.96
Could the 185delAG BRCA1 mutation be an ancient Jewish mutation? Eur J Hum Genet (1998) 0.85
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Evolution at two levels in humans and chimpanzees. Science (1975) 21.07
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med (2001) 16.65
Linkage of early-onset familial breast cancer to chromosome 17q21. Science (1990) 16.21
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell (1993) 13.54
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (1984) 9.64
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics (1992) 9.06
Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science (2000) 8.64
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature (1983) 8.18
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci U S A (1983) 7.01
Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med (1994) 6.59
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 5.35
AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A (1992) 5.24
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer (1995) 5.24
A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol (2007) 5.12
Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science (1987) 5.11
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001) 5.08
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet (1995) 4.86
Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet (1997) 4.86
N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J (2001) 4.85
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA (1997) 4.79
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer (1995) 4.59
Control of cyclin ubiquitination by CDK-regulated binding of Hct1 to the anaphase promoting complex. Science (1998) 4.57
Structural barriers and facilitators in HIV prevention: a review of international research. AIDS (2000) 4.53
Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer (1997) 4.47
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA (1995) 4.45
Involvement of Brca2 in DNA repair. Mol Cell (1998) 4.41
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut (2004) 4.39
Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature (1985) 4.31
BRCA1 is secreted and exhibits properties of a granin. Nat Genet (1996) 4.26
Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation (2000) 4.16
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet (1997) 4.16
Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet (1994) 4.15
Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol (2001) 4.15
Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A (1988) 4.02
Closing in on a breast cancer gene on chromosome 17q. Am J Hum Genet (1992) 3.89
Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science (1993) 3.89
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Linkage of cystic fibrosis to two tightly linked DNA markers: joint report from a collaborative study. Am J Hum Genet (1986) 3.83
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation (1990) 3.83
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature (1996) 3.79
Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet (2001) 3.75
Assessing the risk of breast cancer. N Engl J Med (2000) 3.72
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet (1997) 3.68
Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med (1988) 3.66
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998) 3.60
A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells. Nature (1983) 3.56
Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet (1996) 3.56
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet (2000) 3.50
Growth retardation and tumour inhibition by BRCA1. Nat Genet (1996) 3.47
Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol (2001) 3.35
A clonal marker induced by mutation in mouse intestinal epithelium. Nature (1988) 3.35
Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature (1994) 3.33
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet (1998) 3.28
Population genetics of BRCA1 and BRCA2. Am J Hum Genet (1997) 3.28
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
Responses of plants and invertebrate trophic groups to contrasting herbicide regimes in the Farm Scale Evaluations of genetically modified herbicide-tolerant crops. Philos Trans R Soc Lond B Biol Sci (2003) 3.24
Nonsyndromic deafness DFNA1 associated with mutation of a human homolog of the Drosophila gene diaphanous. Science (1997) 3.21
The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions. Cell (1992) 3.20
BCL-6 protein is expressed in germinal-center B cells. Blood (1995) 3.18
Detecting linkage for genetically heterogeneous diseases and detecting heterogeneity with linkage data. Am J Hum Genet (1986) 3.16